Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It's on Twitter... ASCO Results

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Jun 04, 2023 5:31pm

187 Views

Post# 35479441

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:It's on Twitter... ASCO Results

jimsenior,

If those numbers are the same as the ones released previously, they could have been on a slide that discusses how the results evolved starting from last October. In any case, they told us about 10 times that the data would be current up to May 2023. They cannot fail to actually do that.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?